Ovarian Cancer

A Missouri jury has ordered Johnson & Johnson to pay $72 million in damages to the family of a woman who died from ovarian cancer, which she said was caused by products containing talcum powder.

Safran is the Executive Director of The Identity Shift Project, which aims to bring new perspectives to healing through collaborative art making.

Those who had taken birth control pills prior to their cancer diagnosis had improved progression-free survival compared with those who had not taken contraceptives.

Neoadjuvant chemotherapy is increasingly used in advanced ovarian cancer, even though it has not been shown to improve survival versus primary cytoreduction.

"It's not because there's evidence that they don't work — it's just that there's no evidence at all," Maurie Markman says.

Ten years after founding The Julie Fund for Women's Cancers, President Peter McAvinn's resolve is stronger than ever.

An analysis of data collected on thousands of ovarian cancer patients in California turned up some promising news for women with this diagnosis.

Maurie Markman urges patients with ovarian cancer who have undergone surgery to speak with their gynecologic oncologist and see if IP therapy is right for them.

Melinda Liggett Irwin, discusses The Women's Activity and Lifestyle Study in Connecticut (WALC) study, a randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer.

We sat down with Adele Croteau, a survivor of cervical cancer from Ottawa, Canada, at I Had Cancer's "A Celebration of Shared Experiences Honoring You."

According to professional practice guidelines, women with ovarian cancer should get doses of chemotherapy that are based on their weight. When they receive less than that, a new study has found, the result can be poorer survival.

Kenneth Freundlich, neuropsychologist, Morris Psychological Group, Parsippany, NJ, and FORCE volunteer, discusses the importance of advocacy for patients with hereditary cancers.

Kenneth Freundlich, neuropsychologist, Morris Psychological Group, Parsippany, NJ, and FORCE volunteer, comments on supporting patients with hereditary cancers.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.

CURE Magazine and the Foundation for Women's Cancer have teamed up in CURE's Advocacy Spotlight Partnership program to battle women's cancer through education and shared advocacy on behalf of women suffering from below-the-belt women's cancers.

Backpacking through Nepal, two magicians discover a life-changing secret.

Treatment with a new PARP inhibitor called rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer.

A two-pronged strategy combining the PARP inhibitor Lynparza and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with TNBC and for patients with high-grade serous ovarian cancer.

An oncology nurse navigator writes about her patient's journey with ovarian cancer.

Women who are at high risk of ovarian cancer are more likely to undergo preventive ovary removal if they are proactively offered genetic counseling, a new study has found.